Literature DB >> 29445860

Origin and initiation mechanisms of neuroblastoma.

Shoma Tsubota1, Kenji Kadomatsu2.   

Abstract

Neuroblastoma is an embryonal malignancy that affects normal development of the adrenal medulla and paravertebral sympathetic ganglia in early childhood. Extensive studies have revealed the molecular characteristics of human neuroblastomas, including abnormalities at genome, epigenome and transcriptome levels. However, neuroblastoma initiation mechanisms and even its origin are long-standing mysteries. In this review article, we summarize the current knowledge about normal development of putative neuroblastoma sources, namely sympathoadrenal lineage of neural crest cells and Schwann cell precursors that were recently identified as the source of adrenal chromaffin cells. A plausible origin of enigmatic stage 4S neuroblastoma is also discussed. With regard to the initiation mechanisms, we review genetic abnormalities in neuroblastomas and their possible association to initiation mechanisms. We also summarize evidences of neuroblastoma initiation observed in genetically engineered animal models, in which epigenetic alterations were involved, including transcriptomic upregulation by N-Myc and downregulation by polycomb repressive complex 2. Finally, several in vitro experimental methods are proposed that hopefully will accelerate our comprehension of neuroblastoma initiation. Thus, this review summarizes the state-of-the-art knowledge about the mechanisms of neuroblastoma initiation, which is critical for developing new strategies to cure children with neuroblastoma.

Entities:  

Keywords:  MYCN; Neural crest cells; Neuroblastoma; Schwann cell precursors; Sympathoadrenal progenitors

Mesh:

Year:  2018        PMID: 29445860     DOI: 10.1007/s00441-018-2796-z

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  55 in total

Review 1.  Mechanisms of neuroblastoma regression.

Authors:  Garrett M Brodeur; Rochelle Bagatell
Journal:  Nat Rev Clin Oncol       Date:  2014-10-21       Impact factor: 66.675

2.  The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.

Authors:  Teeara Berry; William Luther; Namrata Bhatnagar; Yann Jamin; Evon Poon; Takaomi Sanda; Desheng Pei; Bandana Sharma; Winston R Vetharoy; Albert Hallsworth; Zai Ahmad; Karen Barker; Lisa Moreau; Hannah Webber; Wenchao Wang; Qingsong Liu; Antonio Perez-Atayde; Scott Rodig; Nai-Kong Cheung; Florence Raynaud; Bengt Hallberg; Simon P Robinson; Nathanael S Gray; Andrew D J Pearson; Suzanne A Eccles; Louis Chesler; Rani E George
Journal:  Cancer Cell       Date:  2012-07-10       Impact factor: 31.743

3.  Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours.

Authors:  Laurel T Bate-Eya; Marli E Ebus; Jan Koster; Ilona J M den Hartog; Danny A Zwijnenburg; Linda Schild; Ida van der Ploeg; M Emmy M Dolman; Huib N Caron; Rogier Versteeg; Jan J Molenaar
Journal:  Eur J Cancer       Date:  2013-12-06       Impact factor: 9.162

4.  MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S.

Authors:  Jean Bénard; Gilda Raguénez; Audrey Kauffmann; Alexander Valent; Hugues Ripoche; Virginie Joulin; Bastien Job; Gisèle Danglot; Sabrina Cantais; Thomas Robert; Marie-José Terrier-Lacombe; Agnès Chassevent; Serge Koscielny; Matthias Fischer; Frank Berthold; Marc Lipinski; Thomas Tursz; Philippe Dessen; Vladimir Lazar; Dominique Valteau-Couanet
Journal:  Mol Oncol       Date:  2008-07-23       Impact factor: 6.603

5.  An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.

Authors:  Ittai Ben-Porath; Matthew W Thomson; Vincent J Carey; Ruping Ge; George W Bell; Aviv Regev; Robert A Weinberg
Journal:  Nat Genet       Date:  2008-05       Impact factor: 38.330

6.  Oncogenic mutations of ALK kinase in neuroblastoma.

Authors:  Yuyan Chen; Junko Takita; Young Lim Choi; Motohiro Kato; Miki Ohira; Masashi Sanada; Lili Wang; Manabu Soda; Akira Kikuchi; Takashi Igarashi; Akira Nakagawara; Yasuhide Hayashi; Hiroyuki Mano; Seishi Ogawa
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

7.  Development of satellite glia in mouse sympathetic ganglia: GDNF and GFR alpha 1 are not essential.

Authors:  Thomas Callahan; Heather M Young; Richard B Anderson; Hideki Enomoto; Colin R Anderson
Journal:  Glia       Date:  2008-10       Impact factor: 7.452

8.  Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries.

Authors:  Valentina Boeva; Caroline Louis-Brennetot; Agathe Peltier; Simon Durand; Cécile Pierre-Eugène; Virginie Raynal; Heather C Etchevers; Sophie Thomas; Alban Lermine; Estelle Daudigeos-Dubus; Birgit Geoerger; Martin F Orth; Thomas G P Grünewald; Elise Diaz; Bertrand Ducos; Didier Surdez; Angel M Carcaboso; Irina Medvedeva; Thomas Deller; Valérie Combaret; Eve Lapouble; Gaelle Pierron; Sandrine Grossetête-Lalami; Sylvain Baulande; Gudrun Schleiermacher; Emmanuel Barillot; Hermann Rohrer; Olivier Delattre; Isabelle Janoueix-Lerosey
Journal:  Nat Genet       Date:  2017-07-24       Impact factor: 38.330

9.  Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival.

Authors:  Hervé J Brisse; Thomas Blanc; Gudrun Schleiermacher; Véronique Mosseri; Pascale Philippe-Chomette; Isabelle Janoueix-Lerosey; Gaelle Pierron; Eve Lapouble; Michel Peuchmaur; Paul Fréneaux; Louise Galmiche; Nathalie Algret; Matthieu Peycelon; Jean Michon; Olivier Delattre; Sabine Sarnacki
Journal:  PLoS One       Date:  2017-09-25       Impact factor: 3.240

10.  Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.

Authors:  Alex Cazes; Lucille Lopez-Delisle; Konstantina Tsarovina; Cécile Pierre-Eugène; Katleen De Preter; Michel Peuchmaur; André Nicolas; Claire Provost; Caroline Louis-Brennetot; Romain Daveau; Candy Kumps; Ilaria Cascone; Gudrun Schleiermacher; Aurélie Prignon; Frank Speleman; Hermann Rohrer; Olivier Delattre; Isabelle Janoueix-Lerosey
Journal:  Oncotarget       Date:  2014-05-15
View more
  34 in total

1.  Maintaining multipotent trunk neural crest stem cells as self-renewing crestospheres.

Authors:  Sofie Mohlin; Ezgi Kunttas; Camilla U Persson; Reem Abdel-Haq; Aldo Castillo; Christina Murko; Marianne E Bronner; Laura Kerosuo
Journal:  Dev Biol       Date:  2019-01-18       Impact factor: 3.582

Review 2.  Biomarkers in Neuroblastoma: An Insight into Their Potential Diagnostic and Prognostic Utilities.

Authors:  Fatima Shawraba; Hussein Hammoud; Yara Mrad; Zahraa Saker; Youssef Fares; Hayat Harati; Hisham F Bahmad; Sanaa Nabha
Journal:  Curr Treat Options Oncol       Date:  2021-09-27

3.  BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma.

Authors:  Wondossen Sime; Qiankun Niu; Yasmin Abassi; Katarzyna Chmielarska Masoumi; Reihaneh Zarrizi; Julie Bonne Køhler; Sven Kjellström; Vito Alessandro Lasorsa; Mario Capasso; Haian Fu; Ramin Massoumi
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

4.  Epigallocatechin-3-gallate and 6-OH-11-O-Hydroxyphenanthrene Limit BE(2)-C Neuroblastoma Cell Growth and Neurosphere Formation In Vitro.

Authors:  Fulvia Farabegoli; Marzia Govoni; Enzo Spisni; Alessio Papi
Journal:  Nutrients       Date:  2018-08-22       Impact factor: 5.717

Review 5.  Targeting anaplastic lymphoma kinase in neuroblastoma.

Authors:  Ganesh Umapathy; Patricia Mendoza-Garcia; Bengt Hallberg; Ruth H Palmer
Journal:  APMIS       Date:  2019-04-03       Impact factor: 3.205

6.  Time-dependent simvastatin administration enhances doxorubicin toxicity in neuroblastoma.

Authors:  Colin C Anderson; Meera Khatri; James R Roede
Journal:  Toxicol Rep       Date:  2020-04-22

Review 7.  Molecular targeting therapies for neuroblastoma: Progress and challenges.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Xinjie Wang; Wa Xian; Frank McKeon; Jennifer Foster; Jia Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2020-11-06       Impact factor: 12.944

8.  NBAT1/CASC15-003/USP36 control MYCN expression and its downstream pathway genes in neuroblastoma.

Authors:  Prasanna Kumar Juvvuna; Tanmoy Mondal; Mirco Di Marco; Subazini Thankaswamy Kosalai; Meena Kanduri; Chandrasekhar Kanduri
Journal:  Neurooncol Adv       Date:  2021-04-09

9.  SNHG16 promotes tumorigenesis and cisplatin resistance by regulating miR-338-3p/PLK4 pathway in neuroblastoma cells.

Authors:  Zhaoying Xu; Yongfa Sun; Danfeng Wang; Huifang Sun; Xiaojun Liu
Journal:  Cancer Cell Int       Date:  2020-06-12       Impact factor: 5.722

Review 10.  A Role for Estrogen Receptor alpha36 in Cancer Progression.

Authors:  Maria Teresa Pagano; Elena Ortona; Maria Luisa Dupuis
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-31       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.